BLUE BELL, Pa., Sept. 3, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO), announced today that Dr. J. Joseph Kim, President and CEO, will be presenting a corporate overview of the company at the Rodman & Renshaw Global Investment Conference and the Stifel Nicolaus Weisel Healthcare Conference.
Rodman & Renshaw Annual Global Investment Conference
September 8-10, 2013
Millennium Broadway Hotel
New York, NY
Tuesday, September 10, 2013
11:15 AM ET
Stifel Nicolaus Weisel Healthcare Conference
September 11-12, 2013
Four Seasons Hotel
Thursday, September 12, 2013
10:55 AM ET
A live and archived webcast of the presentation will be accessible on the homepage of Inovio's website under the webcast tab at www.inovio.com.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved